Healx vs Regard AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Healx employs 1-50 people, while Regard AI has 50-200 employees.

Healx has raised more in total funding at $47M, compared to Regard AI's $30M — a gap of $17M.

Both Healx and Regard AI share the same Awaira Score of 55/100. The Awaira Score is a composite metric that factors in valuation, total funding raised, company stage, employee count, and market category.

Healx was founded by Tim Guilliams in 2014. Regard AI's founder information is not currently available in our database.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.

Healx was founded first in 2014, giving it 3 years of additional market experience. Regard AI was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.